Sage Therapeutics Inc

NASDAQ:SAGE   11:03:52 AM EDT
42.66
-0.31 (-0.72%)
Other Pre-Announcement

Sage Therapeutics Announces Q2 Net Loss Of $2.13/Shr

Published: 08/02/2022 10:52 GMT
Sage Therapeutics Inc (SAGE) - Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress.
Rolling NDA Submission for Zuranolone in Mdd and Ppd Remains on Track, With Completion Expected in Second Half of 2022.
Qtrly Net Loss per Share - Basic and Diluted $2.13.